Articles related to WOMEN'S HEALTH
Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study
Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.
Internal Medicine January 18th 2023
ACP Issues New Osteoporosis Guidance
Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.
Family Medicine/General Practice January 11th 2023
Case 38-2022: A 21-Year-Old Woman with Fatigue and Weight Gain
A mass measuring 4.8 cm by 5.0 cm by 3.9 cm was detected by transabdominal and transvaginal ultrasonography of the abdomen and pelvis. This mass was located along the posterior part of the right hepatic lobe. Following the clinic evaluation, there were two important questions to answer. Initially, was the adrenal tumor malignant or benign? Second, did the lesion secrete hormones?
Endocrinology, Diabetes, Metabolism January 3rd 2023
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy
Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Combination therapy with once-daily oral gonadotropin-releasing hormone-receptor antagonist relugolix plus estradiol and norethindrone acetate in a 12-week course resulted in a significant reduction in bleeding in more than 70% of those in the therapy arms versus less than 20% for the placebo groups.
Family Medicine/General Practice December 21st 2022
Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception
In the US, only two emergency contraceptive methods have been FDA approved: oral levonorgestrel and oral ulipristal acetate. However, the copper IUD appears to be an order of magnitude more effective than the approved methods and so copper IUD is often used. But women prefer the levonorgestrel IUD. This study looked to compare the two IUDs as emergency contraceptives. Among 711 women randomized to copper versus levonorgestrel IUDs, pregnancy rates were 1 in 317 in the levonorgestrel group and 0 in 321, equating to non-inferiority for the levonorgestrel IUD.
Emergency Medicine December 21st 2022